Additionally, pathway-specific interventions, such as AR inhibitors, AGE cross-linking inhibitors, AGE/RAGE signaling pathway inhibitors, selective PKC-β inhibitors, and HBP inhibitors, have demonstrated potential to suppress oxidative stress and ROS generation from the earliest stages of hyperglycemia-induced vascular damage. Here, PRKCB is linked to Hyperglycemia.